Skip to main content
Log in

New treatments for neuromuscular disease: Optimism and obstacles

  • Editorial
  • Published:
Neurotherapeutics

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Müller JS, Mihaylova V, Abicht A, Lochmüller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 2007;9: 1–20.

    Article  PubMed  Google Scholar 

  2. Thirion C, Lochmüller H. Current status of gene therapy for muscle diseases. Drug News Perspect 2007;20: 357–363.

    Article  CAS  PubMed  Google Scholar 

  3. Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 1995;268: E67-E74.

    CAS  PubMed  Google Scholar 

  4. Treatment of neuromuscular diseases. In: Griggs RC, Moxley RT, editors. Advances in neurology, vol. 17. New York: Raven Press; 1977.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lochmüller, H., Griggs, R.C. New treatments for neuromuscular disease: Optimism and obstacles. Neurotherapeutics 5, 497–498 (2008). https://doi.org/10.1016/j.nurt.2008.08.010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.nurt.2008.08.010

Navigation